An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington’s disease
Open Access
- 11 January 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Abstract
Huntington’s disease (HD) is increasingly recognized for diverse pathology outside of the nervous system. To describe the biology of HD in relation to functional progression, we previously analyzed the plasma and CSF metabolome in a cross-sectional study of participants who had various degrees of functional impairment. Here, we carried out an exploratory study in plasma from HD individuals over a 3-year time frame to assess whether differences exist between those with fast or absent clinical progression. There were more differences in circulating metabolite levels for fast progressors compared to absent progressors (111 vs 20, nominal p < 0.05). All metabolite changes in faster progressors were decreases, whereas some metabolite concentrations increased in absent progressors. Many of the metabolite levels that decreased in the fast progressors were higher at Screening compared to absent progressors but ended up lower by Year 3. Changes in faster progression suggest greater oxidative stress and inflammation (kynurenine, diacylglycerides, cysteine), disturbances in nitric oxide and urea metabolism (arginine, citrulline, ornithine, GABR), lower polyamines (putrescine and spermine), elevated glucose, and deficient AMPK signaling. Metabolomic differences between fast and absent progressors suggest the possibility of predicting functional decline in HD, and possibly delaying it with interventions to augment arginine, polyamines, and glucose regulation.Keywords
Funding Information
- Intramural Research Program of the National Institute on Aging, NIH (Z01-AG000297)
This publication has 66 references indexed in Scilit:
- D-serine as a gliotransmitter and its roles in brain development and diseaseFrontiers in Cellular Neuroscience, 2013
- Quinolinic Acid: An Endogenous Neurotoxin with Multiple TargetsOxidative Medicine and Cellular Longevity, 2013
- Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s diseaseJournal of Cell Biology, 2011
- Earliest functional declines in Huntington diseasePsychiatry Research, 2010
- Dopamine and Glutamate in Huntington's Disease: A Balancing ActCNS Neuroscience & Therapeutics, 2010
- Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's DiseaseDiabetes, 2009
- Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein loadThe Journal of Physiology, 2007
- Modulation of Striatal Dopamine Release by Glycine Transport InhibitorsNeuropsychopharmacology, 2005
- Neostriatal and cortical quinolinate levels are increased in early grade Huntington's diseaseNeurobiology of Disease, 2004
- Disrupted Spermine Homeostasis: A Novel Mechanism in Polyglutamine-Mediated Aggregation and Cell DeathJournal of Neuroscience, 2004